GOG-0241 Follow-Up Form (Q) Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer Source Form: NCI FormBuilder:


Versions (3) ▾
  1. 9/19/12
  2. 1/9/15
  3. 1/9/15
Uploaded on:

January 9, 2015

No DOI assigned. To request one please log in.
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Fallopian Tube Cancer NCT01081262 Follow-Up - GOG-0241 Follow-Up Form (Q) - 3126299v1.0

No Instruction available.

  1. StudyEvent: GOG-0241 Follow-Up Form (Q)
    1. No Instruction available.
Header Module
Vital Status
Patient's vital status
Primary Cause of Death
Is the patient lost to follow-Up
Notice Of Progression
Has the patient been diagnosed with a new progression?
What was the method used to determine progression
Ca125 And Other Biomarkers
Notice Of New Primary
Has a new primary cancer or MDS been diagnosed that has not been previously reported? (myelodysplastic syndrome)
Late Adverse Event
Has the patient experienced (prior to diagnosis of recurrence or second primary) any severe (Grade >=3), long term toxicity that has not been previously reported
CTC adverse event attribution code (Adverse Event Attribution Codes 1=Unrelated, 2=Unlikely, 3=Possibly, 4=Probably, 5=Definitely)
Non-protocol Therapy
Is the patient receiving any non-protocol cancer therapy not previously reported?

Similar models